Bumble Inc approved reducing global workforce by 30%. Expects to incur non-recurring charges of $13-18 million and achieve $40 million in annual cost savings. Stock up 17%.
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.